BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

12.72B

Market cap12.72B

Price-Earnings ratio

176.62

Price-Earnings ratio176.62

Dividend yield

—

Dividend yield—

Average volume

1.83M

Average volume1.83M

High today

$66.00

High today$66.00

Low today

$65.29

Low today$65.29

Open price

$65.96

Open price$65.96

Volume

1.60M

Volume1.60M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

As of today, BioMarin(BMRN) shares are valued at $65.68. The company's market cap stands at 12.72B, with a P/E ratio of 176.62.

On 2026-09-11, BioMarin(BMRN) stock moved within a range of $65.29 to $66.00. With shares now at $65.68, the stock is trading +0.6% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 1.6M, compared to an average daily volume of 1.83M.

The stock's 52-week range extends from a low of $49.26 to a high of $70.98.

BMRN News

Investing.com 1d

BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com

...

TipRanks 1d

BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged

H.C. Wainwright analyst Mitchell Kapoor has reiterated their neutral stance on BMRN stock, giving a Hold rating on August 31. Mitchell Kapoor has given his Hol...

Nasdaq 2d

BioMarin Reports Positive Phase 3 Results For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, wit...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More BMRN News

TipRanks 2d

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

BioMarin (BMRN) Pharmaceutical announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO, or vosoritide, in children with hypochondroplasia were...

Simply Wall St 7d

BioMarin Pharmaceutical, What Is Behind The Fresh Attention?

BioMarin Pharmaceutical (BMRN) is back in focus after a settlement and license agreement with Ascendis Pharma over YUVIWEL turned a direct achondroplasia compet...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.